Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A class of heterocyclic compounds with CXCR4 signal channel inhibition activity, and applications thereof

A heterocyclic compound, a technology for inhibiting activity, applied to the composition containing the compound, related to diseases, used in the fields of heterocyclic compounds, age-related macular degeneration, brain inflammation, and diabetic retinopathy

Active Publication Date: 2020-01-10
CGENETECH (SUZHOU CHINA) CO LTD
View PDF6 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although AMD070 entered the second phase of clinical trials, the clinical trials were terminated due to the discovery of hepatotoxicity in preclinical trials

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A class of heterocyclic compounds with CXCR4 signal channel inhibition activity, and applications thereof
  • A class of heterocyclic compounds with CXCR4 signal channel inhibition activity, and applications thereof
  • A class of heterocyclic compounds with CXCR4 signal channel inhibition activity, and applications thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0095] Heterocyclic compound D1, which is synthesized by the following method:

[0096]

[0097] 1) Synthesis of intermediate D1-1

[0098] Ethyl chloroacetoacetate (16.5 g, 100 mmol) and acetamidine hydrochloride (10 g, 106 mmol) were successively dissolved in ethanol (150 mL). 1,8-Diazabicycloundec-7-ene (30.4 g, 200 mmol) was slowly added in an ice-water bath, and stirred overnight at room temperature. Drain the solvent, add dichloromethane (120mL) to dilute, wash with saturated brine (30mL*3), dry the organic phase, and drain the solvent. The residue was dissolved in phosphorus oxychloride (20 mL), and stirred under reflux at 110° C. for 30 min. After cooling to room temperature, most of the phosphorus oxychloride was removed, and the residue was dissolved in ethyl acetate (20 mL) and added dropwise to ice water (100 mL). The aqueous phase was extracted with ethyl acetate (30 mL*3), and the organic phases were combined and dried. After the solvent was spin-dried, th...

Embodiment 2

[0106] Heterocyclic compound D2, which is synthesized by the following method:

[0107]

[0108] 1) Synthesis of intermediate D2-1

[0109] 8-aminoquinoline (200mg, 1.4mmol), intermediate D1-1 (273mg, 1.5mmol), potassium iodide (23mg, 0.14mmol), N,N-diisopropylethylamine (452mg, 3.5mmol) were added into acetonitrile (5 mL) and react overnight at room temperature. Potassium carbonate (386mg, 2.8mmol) was added, the temperature was raised to 90°C, and the reaction was carried out overnight. The reaction solution was spin-dried, added with saturated sodium bicarbonate solution (50 mL), and extracted with dichloromethane (3*20 mL). The organic phases were combined, dried with anhydrous sodium sulfate, filtered, and the filtrate was spin-dried. The residue was purified by column chromatography (dichloromethane:methanol:ammonia water=100:2:1) to obtain a yellow oily intermediate (230 mg, 58%). 1 H NMR (400MHz, CDCl 3 )δ8.79(d, J=2.8Hz, 1H), 8.11(d, J=8.0Hz, 1H), 7.44(dd, J=8...

Embodiment 3

[0115] Heterocyclic compound D3, which is synthesized by the following method:

[0116]

[0117] 1) Synthesis of intermediate D3-1

[0118] The intermediate 8-aminoquinoline (2.9g, 20mmol) was added to absolute ethanol, heated to 90°C, slowly added dropwise into iodomethane (3.4g, 24mmol), sealed and stirred overnight. The solvent was spin-dried, and saturated sodium bicarbonate (50mL) and dichloromethane (60mL) were added, the aqueous phase was extracted twice with dichloromethane (60mL*2), the organic phases were combined, concentrated under reduced pressure, and purified by column chromatography (petroleum Ether:ethyl acetate=50:1) to obtain yellow oil D3-1 (0.90g, 29.8%).

[0119] 2) Synthesis of intermediate D3-2

[0120] Intermediate D3-1 (158mg, 1.9mmol), dissolved in 10mL acetonitrile, added potassium iodide (31.5mg, 0.19mmol), potassium carbonate (524mg, 3.8mmol), D1-1 (219mg, 2.84mmol), reacted overnight at 80°C , spin-dried to obtain an oil, which was purified...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a heterocyclic compound with CXCR4 signal channel inhibition activity, and applications thereof, wherein the heterocyclic compound and the pharmaceutically acceptable salt, theisotope, the isomer and the crystal form structure thereof have a structure represented by a general formula I. The invention also provides applications of the heterocyclic compound with CXCR4 signalchannel inhibition activity. According to the invention, the heterocyclic compound with the CXCR4 signaling pathway inhibition activity can be used as an effective antagonist of a CXCR4 signaling pathway, and can be used for treating or preventing diseases responding to CXCR4 receptor antagonism.

Description

technical field [0001] The present invention relates to a heterocyclic compound having CXCR4 inhibitory activity, a composition comprising the compound, a method for preparing the compound, and the use of the compound in medicine, especially for the treatment of CXCR4-responsive The present invention also relates to the use of said compounds in stem cell harvesting methods for diseases antagonized by the body, such as cancer, cancer metastasis, HIV, HIV-related diseases, brain inflammation, diabetic retinopathy, age-related macular degeneration and retinal angiogenesis Uses, including, for example, facilitating the release and mobilization of stem cells, including hematopoietic stem cells, non-hematopoietic stem cells, and progenitor stem cells, prior to harvesting. The invention belongs to the technical field of medicine. Background technique [0002] CXCR4 belongs to seven transmembrane G-protein coupled receptors (GPCR), and its endogenous ligand is chemokine SDF-1 (stro...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07D401/12C07D401/14C07D471/04A61K31/506A61K31/551A61K31/519A61K31/496A61P35/00A61P35/02A61P31/04A61P31/12A61P25/00A61P3/10A61P31/18A61P17/02A61P11/00A61P11/06A61P9/10A61P17/06A61P19/02A61P21/04A61P13/12A61P17/00A61P1/00A61P27/02A61P27/06
CPCC07D401/12C07D401/14C07D471/04A61P35/00A61P35/02A61P31/04A61P31/12A61P25/00A61P3/10A61P31/18A61P17/02A61P11/00A61P11/06A61P9/10A61P17/06A61P19/02A61P21/04A61P13/12A61P17/00A61P1/00A61P27/02A61P27/06
Inventor 张小虎马海阔郑计岳蔺宇
Owner CGENETECH (SUZHOU CHINA) CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com